跳至主要内容
临床试验/NCT00958321
NCT00958321终止2 期

Prospective Evaluation of PET-CT Scan in Patients With Non-operable or Non-resectable NSCLC Treated by Radical 3-Dimensional Conformal Radiation Therapy

Cancer Trials Ireland1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2007年3月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
终止
入组人数
40
试验地点
1
主要终点
Rate of successful delivery of PET-CT scan based 3-D conformal radiotherapy (Pilot)

研究概览

简要总结

RATIONALE: Diagnostic procedures, such as positron emission tomography and computed tomography, may help learn the extent of disease and allow doctors to plan 3-dimensional conformal radiation therapy.

PURPOSE: This phase II trial is studying the side effects of positron emission tomography and computed tomography and to see how well it works in planning treatment for patients undergoing 3-dimensional conformal radiation therapy for non-small cell lung cancer that cannot be removed by surgery.

This is a clinical study, as the patient will be treated using the PET-CT-GTV: - The pilot study is investigating the technological feasibility - The Phase II study will be a 2-stage Phase II study

详细描述

Pilot Study- Primary Objectives:

  • Prospective evaluation of the technical feasibility of integrating PET-CT fusion in St Luke's Hospital
  • Rate of PET-CT Scan based treatment delivery

Pilot Study- Secondary Objectives:

-Comparison of GTV, PTV and OAR DVHs between conventional 3-DCRT plan and PET-CT based 3-DCRT plan.

Phase II Study- Primary Objective:

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Histologically proven (biopsy or cytology) NSCLC (SCC, Adenocarcinoma, Large Cell)
  • •TNM clinical non-operable stage I/II and non-resectable stage IIIa/b without pleural effusion
  • •Measurable disease
  • •No other malignancy, except non-melanomatous skin cancer, within 5 years prior to participation in this study; the disease-free interval from any prior carcinoma must be continuous
  • •Patient suitable for radical 3-DCRT
  • •ECOG-Performance status ≤ 2 / KPS > or equal to 60
  • •Weight loss <10% within the 3 months prior to diagnosis
  • •No prior radiotherapy to the thorax
  • •Patient is suitable for lung-board immobilisation
  • •No chemotherapy received prior to planning PET-CT scan
  • •Age 18 and over
  • •Provision of written informed consent

排除标准

  • •Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial or if it is felt by the research / medical team that the patient may not be able to comply with the protocol.
  • •FEV1 < 1

研究组 & 干预措施

3-DCRT

Experimental

Patients will receive a total dose of 60-66 Gy in 30-33 fractions with 3-DCRT

干预措施: 3-dimensional conformal radiation therapy (Radiation)

3-DCRT

Experimental

Patients will receive a total dose of 60-66 Gy in 30-33 fractions with 3-DCRT

干预措施: fludeoxyglucose F 18 (Radiation)

3-DCRT

Experimental

Patients will receive a total dose of 60-66 Gy in 30-33 fractions with 3-DCRT

干预措施: radiation therapy treatment planning/simulation (Radiation)

3-DCRT

Experimental

Patients will receive a total dose of 60-66 Gy in 30-33 fractions with 3-DCRT

干预措施: computed tomography (Procedure)

结局指标

主要结局

Rate of successful delivery of PET-CT scan based 3-D conformal radiotherapy (Pilot)

时间窗: 2016

Rate of loco-regional recurrence outside the PET-CT planning target volume (PTV) but within conventional 3-D PTV (Phase II)

时间窗: 2016

次要结局

  • Acute and long-term radiation-induced toxicity(2016)
  • Comparison of dose delivery to organs at risk, according to planning method(2016)

研究者

申办方类型
Network
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验